Evolocumab is a fully human monoclonal IgG2 antibody that targets proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that plays a crucial role in regulating plasma low-density lipoprotein cholesterol (LDL-C) levels. By binding to PCSK9, evolocumab inhibits its interaction with LDL receptors on hepatic cells, thereby increasing the number of receptors available to clear LDL-C from the bloodstream. This mechanism leads to significant reductions in circulating LDL-C levels, making evolocumab a powerful agent in LDL-C-lowering therapies.
Clinically, evolocumab has demonstrated efficacy both as a monotherapy and in combination with statins or other lipid-lowering treatments, achieving LDL-C reductions between 53% and 75%. The biomarker PCSK9 is therefore critical in assessing therapeutic response and guiding evolocumab use. Therapeutic drug monitoring (TDM) can further help optimize dosing strategies, monitor compliance, and prevent unwanted drug interactions. As with other biologics, the use of biosimilar monitoring and detection of anti-drug antibodies (ADAs) is important in assessing immunogenicity and long-term treatment outcomes.
This product is manufactured in Turkey by Matriks Biotek.